Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) and Innoviva (NASDAQ:INVA – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.
Valuation & Earnings
This table compares Shionogi & Co., Ltd. Unsponsored ADR and Innoviva”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shionogi & Co., Ltd. Unsponsored ADR | $3.32 billion | 4.86 | $1.35 billion | $0.90 | 10.53 |
| Innoviva | $411.33 million | 3.29 | $271.17 million | $1.99 | 9.42 |
Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Shionogi & Co., Ltd. Unsponsored ADR and Innoviva, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shionogi & Co., Ltd. Unsponsored ADR | 0 | 0 | 0 | 3 | 4.00 |
| Innoviva | 0 | 1 | 5 | 0 | 2.83 |
Innoviva has a consensus price target of $39.00, suggesting a potential upside of 108.02%. Given Innoviva’s higher probable upside, analysts clearly believe Innoviva is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.
Profitability
This table compares Shionogi & Co., Ltd. Unsponsored ADR and Innoviva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shionogi & Co., Ltd. Unsponsored ADR | 37.95% | 14.32% | 10.24% |
| Innoviva | 44.13% | 22.91% | 16.67% |
Volatility & Risk
Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.
Summary
Innoviva beats Shionogi & Co., Ltd. Unsponsored ADR on 9 of the 15 factors compared between the two stocks.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.
About Innoviva
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
